NCT02951819 – Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma Posted on August 5, 2023 by tsuperadmin -
NCT03464136 – A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn’s Disease Posted on August 5, 2023 by tsuperadmin -
NCT03517722 – A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus Posted on August 5, 2023 by tsuperadmin -
NCT03896061 – A Videographic Study to Evaluate the Impact of a Pulsed Firing Technique on Staple Line Interventions in Laparoscopic Sleeve Gastrectomy Posted on August 5, 2023 by tsuperadmin -
NCT02846545 – SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes Posted on August 5, 2023 by tsuperadmin -
NCT04019041 – A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Posted on August 5, 2023 by tsuperadmin -
NCT03345342 – A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation Posted on August 5, 2023 by tsuperadmin -
NCT01559272 – A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia Posted on August 5, 2023 by tsuperadmin -
NCT00668837 – Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia Posted on August 5, 2023 by tsuperadmin -
NCT02195869 – A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease Posted on August 5, 2023 by tsuperadmin -
The YODA Project